NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Industry news  «  1  2  3  4  5  » 
found files: 758
»18/10/2007 [Industry news]
China's drug industry set to take off

Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest. Their remarks come after the Wuhan Institute of Biological Products (WIBP), a drug firm that is part of the state owned China National Biotec Group (CNBG), signed a deal on September 14 with the US-based health charity PATH to jointly develop - and then produce - a new rotavirus vaccine. Rotavirus kills more than half a million children worldwide - 80 per cent in developing countries. So far, vaccination is the only effective way to combat the disease. Compared with existing rotavirus vaccines developed by pharmaceutical companies Merck and GlaxoSmithKline (GSK), the Chinese version -expected to reach the market in 2012 -will be based on more viral strains, providing wider protection. 'More importantly, we would try our best to lower its production costs, so that it would be priced cheaply to meet the demands of the developing world,' says the project's chief scientist Xu Gelin of WIBP. Separately, Shanghai-based Fosun Pharmaceutical have won the approval of the World Health Organisation (WHO) to market its anti-malaria combination drug Artesunate and Hydrochloride Amodiaquine on 30 August. Artemisinin-derived drugs are a powerful weapon in the fight against malaria, but until now, most Chinese artemisinin makers have only exported raw extracts to pharma giants like Novartis who make the drugs. Despite its reputation of being a low-cost manufacturer of nearly everything, China is not currently a major exporter of drugs, even cheap generics. In the first half of this year, for example, China exported only $7 billion of pharmaceutical products - the bulk of which were active ingredients not drugs. 'The low exports of pharmaceutical products might be caused by the lack of research capacity in the Chinese pharmaceutical sector, but it is also a result of the poor knowledge of international norms and regulations for pharmaceutical products,' says Ken Ren, president of Accelovance (China), a clinical trials consultancy. Xu agrees. By working with PATH, Chinese businesses will be able to tap into the expertise required to deal with issues like international registration, he adds. 'Our production of small molecules [generics] might not be as mature as countries like India, but we have certain advantages in vaccines and other biologics, especially in production costs,' says Xu, adding that this is a result of China's long-established strategy of using cheap vaccines to immunise its own population. Ren says that although producing drugs for the poor countries will not bring Chinese firms big profits, it is a good opportunity to showcase their skills and capabilities. With more multinational drug companies now seeking to outsource production, the experience Chinese firms will gain by supplying cheap drugs to developing countries could help them grab a bigger slice of the outsourcing pie, he adds....   more»

»17/10/2007 [Industry news]
Chinese Medicine Compound Has Satisfactory Anti-cancer Effects On Hepatocellular Carcinoma

Traditional Chinese medicine is world renowned. It has effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method. The research team was led by Dr. Ke-Jun Nan from The First Affiliated Hospital of The School of Medicine of Xi'an Jiaotong University, China. This research will undoubtedly bring comfort to many researchers and patients. HCC is a highly malignant tumor with a very high morbidity and mortality. Despite extensive efforts by many investigators, systemic chemotherapy for HCC has been quite ineffective. Delisheng is a Chinese medicinal compound and is often used in conjunction with chemotherapy for HCC, with satisfactory results. The researchers tried to establish the mechanisms for these effects of delisheng on HCC. Three-dimensional cell culture has been widely used for studying the various molecular processes, because spheroids mimic solid tumors more closely than monolayers. Therefore, the use of three-dimensional culture provides a model for the development of anti-cancer drugs. In this study, cells were cultured with a liquid overlay technique. After the formation of multicellular spheroids, they used the model to perform their experiments. One conclusion reported by the investigators is that three-dimensional cell culture is suitable for the study of a traditional Chinese medicinal compound, and this may help other researchers to find a better model for drug development. Another interesting conclusion is that delisheng had satisfactory anti-cancer effects on HCC, and these were associated with the up-regulation of endostatin. This was made possible by one of delisheng¬°¬Įs components, ginseng, and this may provide a new method of therapy for HCC. Thus three-dimensional cell culture has been widely used for studying the various molecular processes and the development of therapy in recent years; this is the first reported finding in which the model can be used for studying traditional Chinese medicine. Furthermore, the view that the satisfactory effects of delisheng were associated with the up-regulation of endostatin made possible by ginseng might inspire other researchers. The results of this study suggest a promising future for many researchers and HCC patients. First, it provides a new model to study traditional Chinese medicine. Second, it introduces the Chinese medicinal compound delisheng and indicates its further applications....   more»

»26/10/2007 [Industry news]
Genzyme and Sunway to Collaborate on Gene Therapy Program in China

Genzyme Corp. and Sunway Biotech Co. Ltd. announced today that they will collaborate to manufacture, develop, and commercialize the experimental gene therapy Ad2/HIF-1a in China. The product is Genzyme's most advanced gene therapy candidate and is currently in Phase 2 clinical testing in the United States and Europe....   more»

»30/10/2007 [Industry news]
China raises drug licensing standards after scandals over quality control

BEIJING: China is raising quality standards for pharmaceutical licensing following a string of deaths and injuries from faulty drugs, according to a state news agency. The new standard, which takes effect Jan. 1, will tighten rules that currently let a producer obtain a license if three "severe defects" are found but corrected, the Xinhua News Agency said Monday. In future, no such defects in the drug manufacturing process will be allowed, said Xinhua. It said submission of false data by drug makers was a severe defect but gave no examples of others. "The new standards have strengthened supervision over weak links in quality control of drug manufacturers," the director of the State Food and Drug Administration's drug safety supervision department, Bian Zhenjia, was quoted as saying. The government launched an overhaul of drug regulation and licensing this year after a string of deaths and injuries blamed on defective or phony drugs. A former SFDA director was executed in July on charges that he took bribes to approve untested drugs. In February, the government ordered a review of 170,000 drug production licenses granted during his time in office to see that they were properly granted. The new rules on "good manufacturing practice" also give additional technical specifications, Xinhua said. "The changes mainly dwell on technological requirements on management which concerns areas including personnel qualifications, production process, quality control and document verification in a bid to ensure drug quality," Bian was quoted as saying....   more»

»26/10/2007 [Industry news]
Genesis Technology Group Retains CCG Elite

Genesis Technology Group Inc. (to be known as Genesis Pharmaceutical Enterprises, Inc.) ("GTEC" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign....   more»

»22/10/2007 [Industry news]
TCM, Western medicine can be integrated for better health - minister

CHINA'S health minister's recent support for traditional Chinese medicine (TCM) should probably help instill renewed confidence in TCM as a healing art. Steadily eclipsed by Western medicine, this art is increasingly challenged to defend its existence on scientific terms....   more»

»29/10/2007 [Industry news]
Benda subsidiary developing potential AIDS vaccine

Benda Pharmaceutical, a Chinese pharmaceutical company that produces traditional Chinese and conventional medicines, as well as Gendicine, the world's first commercialized gene therapy medicine for cancer has said that its subsidiary SiBiono has developed an anti-AIDS gene therapy. This marks SiBiono's and Benda's anticipated entry into the $14 billion Chinese anti-AIDS drug market...   more»

»03/11/2007 [Industry news]
QBIC connects with China by signing a framework partnership agreement

The Quebec Biotechnology Innovation Centre (QBIC) today signed a framework agreement with BioBay - Suzhou Industrial Park, a science and industrial park in Shanghai. This agreement will allow both organizations to develop exchange projects and implement bio-incubator operating practices. Moreover, their respective companies will receive invaluable guidance in their international development efforts. Perhaps HMGov might sponsor a similar arrangement...   more»

Sanofi-Aventis »02/11/2007 [Industry news]
Sanofi Pasteur wins Flu Vaccine contract for Beijing

In October Beijing released the 2007 tendering results for influenza vaccine, marking the first time the vaccine has been included in Beijing's reimbursement system. Sanofi Pasteur will supply 1.2 million doses of the influenza vaccine, an amount that should generate RMB 48 million for the company. Four domestic manufacturers, Sinovac, Jiangsu Yanshen, Zhejiang Tianyuan, and Dalian Yalifeng, will provide the remaining 1.6 million doses. Five additional manufacturers, Changchun Changsheng, Shanghai Institute of Biological Products, Berna, GSK, and Novartis, also took part in the bidding but were not selected to provide the drug. In September, Beijing announced that it would purchase 2.8 million doses of the influenza vaccine for approximately RMB 100 million to provide free flu vaccinations for Beijing citizens over 60 years of age and to subsidize vaccinations for schoolchildren. Vaccines from Sanofi Pasteur with a tendering price of RMB 40 will be used to vaccinate schoolchildren and charged at RMB 20. Vaccines from four domestic producers with a tendering price of RMB 34 will be provided free to Beijing's senior citizens. The influenza vaccine is a Class II vaccine in China and therefore is not covered by the national government reimbursement system....   more»

»07/11/2007 [Industry news]
China blacklists 16 drugs, medical equipments posting "illegal" ads

China's pharmaceutical watchdog has warned 16 companies that they risk losing their advertising licenses after they published "illegal" ads that exaggerated the benefits of their products. The 16 ads for drugs and medical equipment were identified by the State Food and Drug Administration (SFDA) on its website Wednesday....   more»

»11/11/2007 [Industry news]
McVicar announces first order for its anti-AIDS intermediate chemical

McVicar Resources Inc. ("McVicar") is pleased to announce that its Chinese subsidiary, Zhejiang Hongbo Chemical Co. Ltd. ("Hongbo") has received an initial order for its intermediate chemicals used in anti-AIDS drugs from a major pharmaceutical company in South Korea. The order valued at approximately 5 million RMB calls for the immediate delivery of 6,000 kg of the intermediate chemical. The South Korean company also expressed its intention to purchase a further 5,000 kg of the intermediate chemical for future delivery....   more»

»18/11/2007 [Industry news]
Blackstone seeks to help Chinese firms go global

The Blackstone Group is considering helping more Chinese firms expand abroad, said Hamilton James, the global private equity firm's president and chief operating officer on Thursday....   more»

»18/11/2007 [Industry news]
Singapore, China team up in traditional Chinese medicine centre

A joint venture between Singapore General Hospital and a Shanghai group will provide traditional Chinese medicine to patients in South-East Asia starting next month, organizers said on Saturday. The 2.8-million-Singapore dollar (1.8-million US dollar) centre to be called Ban Zhong Tang, meaning "hall of treasures," is a tie-up between SingHealth and the Shanghai Hospital Development Centre...   more»

»15/11/2007 [Industry news]
Government-led medical reform expected

The government-led idea has won on some key issues. But parts of the idea may hurt the dynamic core of the medical system, which disappoints me to some extent," said Gu Xin, editor of the seventh medical reform scheme established by Beijing Normal University. He is also a representative who advocates the "market-led idea" and a senior analyst with the Center for Human and Economic Development Studies at Peking University. Gu spoke frankly with the China Economic News Weekly at the end of October....   more»

»13/11/2007 [Industry news]
China gets serious on drug GMP; safety pact with FDA imminent

As of next year Chinese pharmaceutical manufacturers will face a tougher time gaining good manufacturing practice (GMP) certification after the country's regulator signalled new and stricter standards were on the way....   more»

»14/11/2007 [Industry news]
Pharmarama to source comparator drug services in China

Pharmarama, a leader in the procurement of pharmaceutical products for comparator trials and named patient programs, today announced today at BIO-Europe 2007 in Hamburg, Germany, that the firm will be providing complete services to source comparator drugs for clinical trials in China. Pharmarama believes that it is the first global clinical trial supply company to have the necessary relationships and protocols in place to source comparator drugs both into and out of mainland China....   more»

»19/11/2007 [Industry news]
Monstrous drug wholesale market set to open in Shenzhen

According to the International Business Daily, the Shenzhen Drug Wholesale Market will open in December after final decoration is complete. The market was built with a RMB 500 million investment from Southern Traditional Chinese Medicine (TCM) Harbor. The new market occupies nearly 10,000 square meters in Shenzhen's downtown Luohu District. One thousand domestic and multinational pharmaceutical companies have agreed to take part in the Shenzhen market. Once open, the Shenzhen Drug Wholesale Market will be the largest drug import and export base in China and the largest wholesale drug market in the Asia-Pacific region. The market will have specialized business areas for TCM and western drug and health products. Marketed products fall into nine classifications, including prescription drugs, OTC drugs, health products, cosmetics, and TCMs. According to estimates, nearly 30,000 products will be sold in the Shenzhen wholesale market. According to Southern TCM Harbor, the Shenzhen market will provide services including brand exhibition and retail to pharmaceutical enterprises. The market will establish a permanent location for product and brand demonstrations and will hold a yearly business and trade week to help companies expand their markets....   more»

»19/11/2007 [Industry news]
SFDA targets generics in ongoing revision of tech transfer regulations

According to Ding Jianhua, Director of the Chemical Drug Registration Department of the SFDA, a new `Registration Regulation on Drug Technology Transfer' has been in the works since July. The document will work in conjunction with the previously launched `Drug Registration Resolution (No. 28)'. Ding's comments were made during the opening ceremony of the 10th China Pharmaceutical High-tech Transfer Summit on November 8. The new regulations will encourage technology transfer, reduce the number of generics, and ensure drug quality. Several major modifications include: 1. removing technology transfer restrictions on drugs that are in the New Drug Monitoring Period 2. differentiating between technology transfer for new drugs and for generics - when a new approval is granted for transfer of a generic technology, the preceding approval will be disqualified (thus the total number of approvals for generics will not increase due to tech transfer) 3. clarifying liability - the buyer will be liable when drug safety or quality concerns arise According to Rui Guozhong, Director of China Pharmaceutical Technology Transfer Center (CPTTC), the draft of the new regulations will be finished by the end of this year and will take effect in early 2008....   more»

»03/12/2007 [Industry news]
China shuts down 300 drug, medical instrument manufacturers

China has shut down 300 drug and medical instrument manufacturers for bad quality products in a national campaign since last July, said China's drug watchdog here Monday. The campaign to correct malpractice in the pharmacy industry is showing results, said Wu Zhen, deputy director of the State Food and Drug Administration (SFDA), at a press conference....   more»

»07/12/2007 [Industry news]
SFDA strengthens management over APIs

The Deputy Commissioner of the State Food and Drug Administration (SFDA), Wu Zhen, recently stated that the SFDA plans to strengthen its administration over APIs produced by chemical enterprises. He stated that illegal use of chemical products as APIs for the production of drugs is a key contributing factor leading to low-quality and fake drugs. According to Wu, the agency is investigating Chinese enterprises involved in supplying and using chemical raw materials and will include them in its supervision system....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.